Nature's clarion call of antibacterial resistance: Are we listening?

Current Opinion in Investigational Drugs

Volumn 7, Issue 2, 2006, Pages 158-166

  Theuretzbacher, Ursula ^a   Toney, Jeffrey H ^b  

^a Center For Anti Infective Agents Vienna   (Austria)

^b MONTCLAIR STATE UNIVERSITY   (United States)

Author keywords

Antibiotic resistance; Antibiotics; Drug development; Efflux; Virulence

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AUROGRAB; AZTREONAM; BETA LACTAMASE INHIBITOR; BSYX A110; CEFTAZIDIME; CEPHALOSPORIN; CY 401; CY 403; DALBAVANCIN; ETI 211; GLYCOPEPTIDE; GLYCOSYLTRANSFERASE; IMIPENEM; JUVAVAX; METICILLIN; ORITAVANCIN; PEPTIDOGLYCAN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAMOPLANIN; RNA POLYMERASE; RX 01; SORTASE; STAPHA HP; STAPHYLOCOCCUS VACCINE; TEFIBAZUMAB; TELAVANCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VERONATE;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; COMMUNITY CARE; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; ENTEROBACTERIACEAE; ENTEROCOCCUS; HOSPITAL CARE; HUMAN; INFECTION; MULTIDRUG RESISTANCE; PATIENT CARE; PSEUDOMONAS; REVIEW; STAPHYLOCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; BETA-LACTAMASES; CEPHALOSPORINS; CLINICAL TRIALS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; HUMANS; MEMBRANE TRANSPORT MODULATORS; VIRULENCE; VIRULENCE FACTORS;

EID: 32544457992     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. National Nosocomial Infections Surveillance System: National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control (2004) 32(8):470-485.
2. The European Antimicrobial Resistance Surveillance System (EARSS). European Commission and the Dutch Ministry of Health, Welfare and Sports, the Netherlands (2005). http://www.earss.rivm.nl
3. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr: Trends in antimicrobial drug development: Implications for the future. Clin Infect Dis (2004) 38(9):1279-1286.
4. Bush K: Antibacterial drug discovery in the 21st century. Clin Microbiol Infect (2004) 10(Suppl 4):10-17.
5. Livermore DM: The need for new antibiotics. Clin Microbiol Infect (2004) 10(Suppl 4):1-9.
6. Chopra I, Hesse L, O'Neill AJ: Exploiting current understanding of antibiotic action for discovery of new drugs. Symp Ser Soc Appl Microbiol (2002) 31:4S-15S.
7. Ernst & Young: Beyond Borders. Global Biotechnology Report (2005): June 2005.
8. Bayer AG: Bayer HealthCare: Majority holding in anti-infectives research acquired by Santo Holding AG. Press Release (2005): November 03.
9. Van Bambeke F: Glycopeptides in clinical development: Pharmacological profile and clinical perspectives. Curr Opin Pharmacol (2004) 4(5):471-478.
10. Toyama accelerates development of T-3811. Pharma Jpn (2002) 1824:December 16.
11. Strahilevitz J, Hooper DC: Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: Direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin. Antimicrob Agents Chemother (2005) 49(5):1949-1956.
12. Appelbaum PC, Pankuch GA, Bozdogan B, Lin G, Jacobs MR, Patel MV, Gupte SV, Jafri MA, De Souza NJ, Khorakiwala HF: Activity of the new quinolone WCK 771 against pneumococci. Clin Microbiol Infect (2005) 11(1):9-14.
13. Wockhardt Ltd: New drug discovery - pipeline. Company World Wide Web Site (2005):December 05.
14. Daiichi Pharmaceutical Co Ltd: Interim financial results of FY 2003 (April 1, 2003 - September 30, 2003). Company Presentation (2003): October 31.
15. Procter & Gamble Pharmaceuticals Inc: Drug development pipeline: PGE-9602021. Company Communication (2004):April 23.
16. TaiGen Biotechnology Co Ltd: TaiGen initiates phase 1b trial of a novel quinolone antibiotic with broad-spectrum activity toward drug-sensitive and resistant bacteria. Press Release (2005):June 18.
17. Vertex Pharmaceuticals Inc: Product pipeline. Company World Wide Web Site (2004):November 03.
18. Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, Cai Y, Flamm RK: In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother (2003) 47(10):3260-3269.
19. Abbott Laboratories: Abbott Laboratories - 2003 R&D update. Company Presentation (2003):May 29
20. D'Andrea S, Zheng ZB, Denbleyker K, Fung-Tomc JC, Yang H, Clark J, Taylor D, Bronson J: Synthesis and antibacterial activity of dihydro-1,2-oxazine and 2-pyrazoline oxazolidinones: Novel analogs of linezolid. Bioorg Med Chem Lett (2005) 15(11):2834-2839.
21. Sood R, Rao M, Singhal S, Rattan A: Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages. Int J Antimicrob Agents (2005) 25(6):464-468.
22. Reck F, Zhou F, Girardot M, Kern G, Eyermann CJ, Hales NJ, Ramsay RR, Gravestock MB: Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem (2005) 48(2):499-506.
23. Phillips OA: Antibacterial agents: Patent highlights January to June 2004. Curr Opin Investig Drugs (2004) 5(8):799-808.
24. AstraZeneca plc: AstraZeneca R&D pipeline: NCEs 25 July 2002. Company World Wide Web Site (2002):July 25.
25. Gravestock MB: Recent developments in the discovery of novel oxazolidinone antibacterials. Curr Opin Drug Discov Devel (2005) 8(4):489-477.
26. Wang G, Niu D, Qiu YL, Phan LT, Chen Z, Polemeropoulos A, Or YS: Synthesis of novel 6,11-O-bridged bicyclic ketolides via a palladium-catalyzed bis-allylation. Org Lett (2004) 6(24):4455-4458.
27. Advanced Life Sciences Inc: Drug Development pipeline/infectious disease. Company World Wide Web Site (2005): August 08.
28. Liang CH, Yao S, Chiu YH, Leung PY, Robert N, Seddon J, Sears P, Hwang CK, Ichikawa Y, Romero A: Synthesis and biological activity of new 5-O-sugar modified ketolide and 2-fluoro-ketolide antibiotics. Bioorg Med Chem Lett (2005) 15(5):1307-1310.
29. Optimer Pharmaceuticals Inc: Optimer Pharmaceuticals: About us; R&D; product pipeline. Company World Wide Web Site (2004):November 03.
30. Rothstein DM, Hartman AD, Cynamon MH, Eisenstein BI: Development potential of rifalazil. Expert Opin Investig Drugs (2003) 12(2):255-271.
31. Anton PM, O'Brien M, Kokkotou E, Eisenstein B, Michaelis A, Rothstein D, Paraschos S, Kelly CP, Pothoulakis C: Rifalazil treats and prevents relapse of Clostridium difficile-associated diarrhea in hamsters. Antimicrob Agents Chemother (2004) 48(10):3975-3979.
32. Gordeev MF, Hackbarth C, Barbachyn MR, Banitt LS, Gage JR, Luehr GW, Gomez M, Trias J, Morin SE, Zurenko GE, Parker CN et al: Novel oxazolidinone-quinolone hybrid antimicrobials. Bioorg Med Chem Lett (2003) 13(23):4213-4216.
33. Hubschwerlen C, Specklin JL, Sigwalt C, Schroeder S, Locher HH: Design, synthesis and biological evaluation of oxazolidinonequinolone hybrids. Bioorg Med Chem (2003) 11(10):2313-2319.
34. Biovertis AG: Biovertis to acquire Morphochem. Press Release (2005):December 01.
35. Weiss WJ, Petersen PJ, Murphy TM, Tardio L, Yang Y, Bradford PA, Venkatesan AM, Abe T, Isoda T, Mihira A, Ushirogochi H et al: In vitro and in vivo activities of novel 6-methylidene penems as β-lactamase inhibitors. Antimicrob Agents Chemother (2004) 48(12):4589-4596.
36. Buynak JD: The discovery and development of modified penicillin- and cephalosporin-derived β-lactamase inhibitors. Curr Med Chem (2004) 11(14):1951-1964.
37. Jones RN, Biedenbach DJ, Sader HS, Fritsche TR, Toleman MA, Walsh TR: Emerging epidemic of metallo-β-lactamase-mediated resistances. Diagn Microbiol Infect Dis (2005) 51(2):77-84.
38. Toney JH, Moloughney JG: Metallo-β-lactamase inhibitors: Promise for the future? Curr Opin Investig Drugs (2004) 5(8):823-826.
39. Toney JH: Metallo-β-lactamase inhibitors: Could they give old antibacterials new life? Curr Opin Investig Drugs (2003) 4(2):115-116.
40. Sanschagrin F, Levesque RC: A specific peptide inhibitor of the class B metallo-β-lactamase L-1 from Stenotrophomonas maltophilia identified using phage display. J Antimicrob Chemother (2005) 55(2):252-255.
41. Gomes CM, Frazao C, Xavier AV, Legall J, Teixeira M: Functional control of the binuclear metal site in the metallo-β-lactamase-like fold by subtle amino acid replacements. Protein Sci (2002) 11(3):707-712.
42. Callebaut I, Moshous D, Mornon JP, de Villartay JP: Metallo-β-lactamase fold within nucleic acids processing enzymes: The β-CASP family. Nucleic Acids Res (2002) 30(16):3592-3601.
43. Wickens M, Gonzalez TN: Molecular biology. Knives, accomplices, and RNA. Science (2004) 306(5700):1299-1300.
44. Poinsignon C, Moshous D, Callebaut I, de Chasseval R, Villey I, de Villartay JP: The metallo-β-lactamase/β-CASP domain of Artemis constitutes the catalytic core for V(D)J recombination. J Exp Med (2004) 199(3):315-321.
45. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R et al: Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel agents for combination therapy. Antimicrob Agents Chemother (2001) 45(1):105-116.
46. Kriengkauykiat J, Porter E, Lomovskaya O, Wang-Beringer A: Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2005) 49(2):565-570.
47. Kaatz GW: Bacterial efflux pump inhibition. Curr Opin Investig Drugs (2005) 6(2):191-198.
48. Li XZ, Nikaido H: Efflux-mediated drug resistance in bacteria. Drugs (2004) 64(2):159-204.
49. Coban AY, Ekinci B, Durupinar B: A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy (2004) 50(1):22-26.
50. Barrett JF: MC-207110 (Daiichi Seiyaku/Microcide Pharmaceuticals). Curr Opin Investig Drugs (2001) 2(2):212-215.
51. Chen L, Yang J, Yu J, Yao Z, Sun L, Shen Y, Jin Q: VFDB: A reference database for bacterial virulence factors. Nucleic Acids Res (2005) 33(Database issue):D325-D328.
52. Brogden K, Roth JA, Stanton TB, Bolin CA, Minion FC, Wannemuehler MJ (Eds): Virulence Mechanisms of Bacterial Pathogens. ASM Press, Washington, DC, USA (2000).
53. Lee YM, Almqvist F, Hultgren SJ: Targeting virulence for antimicrobial chemotherapy. Curr Opin Pharmacol (2003) 3(5):513-519.
54. Raffa RB, Iannuzzo JR, Levine OR, Saeid KK, Schwartz RC, Sucic NT, Terleckyj OD, Young JM: Bacterial communication ('quorum sensing') via ligands and receptors: A novel pharmacologic target for the design of antibiotic drugs. J Pharmacol Exp Ther (2005) 312(2):417-423.
55. Svensson A, Larsson A, Emtenas H, Hedenstrom M, Fex T, Hultgren SJ, Pinkner JS, Almqvist F, Kihlberg J: Design and evaluation of pilicides: Potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem (2001) 2(12):915-918.
56. Ng TW, Akman L, Osisami M, Thanassi DG: The usher N terminus is the initial targeting site for chaperone-subunit complexes and participates in subsequent pilus biogenesis events. J Bacteriol (2004) 186(16):5321-5331.
57. SIGA Pharmaceuticals Inc: SIGA announces identification of lead antibiotic compound. Press Release (1998):September 09.
58. Jones CH, Bolken TC, Jones KF, Zeller GO, Hruby DE: Conserved DegP protease in Gram-positive bacteria is essential for thermal and oxidative tolerance and full virulence in Streptococcus pyogenes. Infect Immun (2001) 69(9):5538-5545.
59. Alekshun MN, Bartlett VJ, Bowser T, Verma A, Grier M, Warchol T, Ohemeng K, Levy SB, Tanaka SK: Novel anti-infection agents: Small molecule transcription factor modulators. ICAAC (2004):Abs F-1523.
60. Neely AN, Holder IA, Wiener-Kronish JP, Sawa T: Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns (2005) 31(2):153-158.
61. Frank DW, Vallis A, Wiener-Kronish UP, Roy-Burman A, Spack EG, Mullaney BP, Megdoud M, Marks JD, Fritz R, Sawa T: Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis (2002) 186(1):64-73.
62. Kruger RG, Barkallah S, Frankel BA, McCafferty DG: Inhibition of the Staphylococcus aureus sortase transpeptidase SrtA by phosphinic peptidomimetics. Bioorg Med Chain (2004) 12(13):3723-3729.
63. Boularot A, Giglione C, Artaud I, Meinnel T: Structure-activity relationship analysis and therapeutic potential of peptide deformylase inhibitors. Curr Opin Investig Drugs (2004) 5(8):809-822.
64. Bowker KE, Noel AR, MacGowan AP: In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int J Antimicrob Agents (2003) 22(6):557-561.
65. Fritsche TR, Sader HS, Cleeland R, Jones RN: Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. Antimicrob Agents Chemother (2005) 49(4):1468-1476.
66. Kuhl A, Svenstrup N, Ladel C, Otteneder M, Binas A, Schiffer G, Brands M, Lampe T, Ziegelbauer K, Rubsamen-Waigmann H, Haebich D et al: Biological characterization of novel inhibitors of the Gram-positive DNA polymerase IIIC enzyme. Antimicrob Agents Chemother (2005) 49(3):987-995.
67. 3-hydroxybutyl 6-(3′-ethyl-4′-methylanilino) uracil. Antimicrob Agents Chemother (2002) 46(12):3770-3775.
68. Butler MM, Skow DJ, Stephenson R, Lamarr W, Foster K: Low resistance rates determined for a novel class of bactericidal DNA polymerase inhibitors. ICAAC (2001) 41:Abs C1-139.
69. Haebich D, Ehlert K, Kuhl A, Ladel C, Svenstrup N, Brands M, Lampe T, Ziegelbauer K: In vitro and in vivo antimicrobial activity of novel 6-aminouracil-DNA polymerase inhibitors. ICAAC (2003) 43:Abs F-2155.
70. Payne DJ, Warren PV, Holmes DJ, Ji Y, Lonsdale JT: Bacterial fatty-acid biosynthesis: A genomics-driven target for antibacterial drug discovery. Drug Discov Today (2001) 6(10):537-544.
71. Kodali S, Galgoci A, Young K, Painter R, Silver LL, Herath KB, Singh SB, Cully D, Barrett JF, Schmatz D, Wang J: Determination of selectivity and efficacy of fatty acid synthesis inhibitors. J Biol Chem (2005) 280(2):1669-1677.
72. Freiberg C, Brunner NA, Schiffer G, Lampe T, Pohlmann J, Brands M, Raabe M, Habich D, Ziegelbauer K: Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J Biol Chem (2004) 279(25):26066-26073.
73. Nie Z, Perretta C, Lu J, Su Y, Margosiak S, Gajiwala KS, Cortez J, Nikulin V, Yager KM, Appelt K, Chu S: Structure-based design, synthesis, and study of potent inhibitors of β-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J Med Chem (2005) 48(5):1596-1609.
74. Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA et al: Discovery of a novel and potent class of Fabl-directed antibacterial agents. Antimicrob Agents Chemother (2002) 46(10):3118-3124.
75. Brotz-Oesterhelt H, Beyer D, Kroll HP, Endermann R, Ladel C, Schroeder W, Hinzen B, Raddatz S, Paulsen H, Henninger K, Bandow JE et al: Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med (2005) 11(10):1082-1087.
76. Toke O: Antimicrobial peptides: New candidates in the fight against bacterial infections. Biopolymers (2005) 80(6):717-735.
77. Reddy KV, Yedery RD, Aranha C: Antimicrobial peptides: Premises and promises. Int J Antimicrob Agents (2004) 24(6):536-547.
78. Bals R: Epithelial antimicrobial peptides in host defense against infection. Respir Res (2000) 1(3):141-150.
79. Marshall SH, Arenas G: Antimicrobial peptides: A natural alternative to chemical antibiotics and a potential for applied biotechnology. Electron J Biotechno (2003) 6(3):271-284.
80. McPhee JB, Scott MG, Hancock RE: Design of host defence peptides for antimicrobial and immunity enhancing activities. Comb Chem High Throughput Screen (2005) 8(3):257-272.
81. Sulakvelidze A, Alavidze Z, Morris JG Jr: Bacteriophage therapy. Antimicrob Agents Chemother (2001) 45(3):649-659.
82. Liu J, Dehbi M, Moeck G, Arhin F, Bauda P, Bergeron D, Callejo M, Ferretti V, Ha N, Kwan T, McCarty J et al: Antimicrobial drug discovery through bacteriophage genomics. Nat Biotechnol (2004) 22(2):185-191.
83. Inhibitex Inc: Inhibitex initiates enrollment in pivotal phase III trial for Veronate. Press Release (2004):June 30.
84. NeuTec Pharma plc: NeuTec Pharma commences phase III trials for MRSA drug, Aurograb. Press Release (2004):May 05.
85. Inhibitex Inc: Inhibitex initiates enrollment in phase II trial for Aurexis. Press Release (2004):March 08.
86. Biosynexus Inc: Biosynexus' new anti-microbial agent destroys MRSA biofilm; only compound shown to be capable of eliminating biofilm and killing S aureus. Press Release (2003):October 30.
87. Nabi Biopharmaceuticals: Nabi Biopharmaceuticals initiates S Epidermidis vaccine phase I study. Press Release (2005):May 25.
88. Jones SM, Li J, Ferreira CS, Shah K, Lee S, Pincus SE, Spitalny GL, Casey LS, Kreiswirth B, Mohamed N: Complete protection against Staphylococcus aureus bacteremia using a novel dual antibody therapeutic approach. ICAAC (2004) 44:Abs F-724.
89. CytoGenix Inc: CytoGenix scientists discover a new class of antibacterial agents, file for US patent. Press Release (2003):June 03.
90. CytoGenix Inc: CytoGenix Inc: Product pipeline. Company World Wide Web Site (2004):October 27.
91. CytoGenix Inc: CytoGenix Inc announces a new product in development. Press Release (2005):March 31.
92. Juvans BioTherapeutics Inc: Juvaris BioTherapeutics Inc - company and product information. Company World Wide Web Site (2003):September 17.
93. Pfizer Inc: Pfizer Inc third quarter 2005 performance report. PRESS RELEASE (2005):October 20.
94. Comparison of telavancin and vancomycin for complicated skin and skin structure infections with a focus on methicillin-resistant Staphylococcus aureus. National Institutes of Health, Bethesda, MD, USA (2004). http://www.clinicaltrials.gov/ct/show/NCT00091819?order=1
95. InterMune Inc: InterMune announces divestiture of oritavancin. Press Release (2005):December 27.
96. Biosearch Italia SPA: Biosearch Italia announces that Genome Therapeutics has initiated phase II study of ramoplanin for the treatment of Clostridium difficile-associated diarrhea. Press Release (2003):February 20.
97. Rib-X Pharmaceuticals Inc: Rib-X, novel antibiotic discovery firm, launches first clinical trial from ribosome-based technology platform. Press Release (2005):December 19.
98. Combinature Biopharm AG: Pipeline. Company World Wide Web Site (2005):August 16.
99. Ecopia BioSciences Inc: Ecopia discovers new antibiotic compound having activity against drug-resistant bacteria. Press Release (2003):September 11.
100. Affinium Pharmaceuticals: Affinium Pharmaceuticals acquires novel antibacterial program from GlaxoSmithKline. Press Release (2003):February 26.
101. SIGA Technologies Inc: SIGA acquires antibiotic technology from University of California. Press Release (2000):December 19.
102. Alchemia Pty Ltd: Alchemia's technology: Discovery of new antibacterial agents. Company World Wide Web Site (2001):July 10.
103. Targanta Therapeutics Inc: Targanta Therapeutics announces discovery of new class of agents to target Staphylococcus aureus. Press Release (2005):December 19.
104. Shionogi: Finibax 0.25 g IV solution. Pharma Jpn (2005) 1960:21.
105. Taxotere and two new anitbiotics launched in Japan. Scrip (1997) 2245:17.
106. Basilea Pharmaceutica AG: Basilea enters a global collaboration with Johnson & Johnson's affiliate Cilag AG International for Basilea's phase III, first-in-class antibiotic ceftobiprole (BAL5788). Press Release (2005):February 03.
107. Basilea Pharmaceutics AG: Basilea's first-in-class antibiotic ceftobiprole (BAL5788) moves into phase III. Press Release (2004):November 04.
108. Meiji licenses carbapenem from Wyeth Lederle. Pharma Jpn (2002) 1789:2.
109. Cerexa Inc: Cerexa Inc initiates phase 2 clinical trial of PPI-0903. Press Release (2005):October 19.
110. Sankyo Co Ltd: R&D meeting 2005. Company Presentation (2005):March 22.
111. Garvey R: Interscience Conference on Antimicrobial Agents and Chemotherapy - 40th Meeting (Part VIII), Toronto, Canada. IDdb Meeting Report (2000):September 17-20.
112. Protez Pharmaceuticals Inc: Protez Pharmaceuticals Inc to develop & commercialize breakthrough antibiotic; announces licensing agreement with Sumitomo Pharmaceuticals Co Ltd. Press Release (2005):May 17.